Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
European quality of life scale (5 dimensions) (EQ-5D)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients \> 18 years of age
Patients who have a life expectancy of at least 12 weeks
Patients with histological or cytologically documented HCC
Patients must have at least one tumor lesion that meets both of the following criteria:
* The lesion can be accurately measured in at least one dimension according to response evaluation criteria in solid tumors (RECIST)
* The lesion has not been previously treated with local therapy
Patients who have an ECOG PS (Eastern Cooperative Oncology Group Performance Status) of 0 or 1
Cirrhotic status of Child-Pugh class A.
Patients who give written informed consent prior to any study specific screening procedures with the understanding that the patient has the right to withdraw from the study at any time.
You may not be if
History of cardiac disease: congestive heart failure \> New York Heart Association (NYHA) class 2; active coronary artery disease (CAD); cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin), or uncontrolled hypertension. Myocardial infarction more than 6 months prior to study entry is permitted.
Abnormalities of the cornea based on history (e.g. dry eye syndrome, Sogren's syndrome) including congenital abnormality (e.g. Fuch's dystrophy), abnormal slit-lamp examination using a vital dye (e.g. fluorescein, Bengal-Rose), and/or an abnormal corneal sensitivity test (Schirmer test or similar tear production test).
History of interstitial lung disease (ILD).
Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.
Previous treatment with yttrium-90 spheres
Any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study.
Uncontrolled ascites (defined as not easily controlled with diuretic treatment)
Clareo Health | Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
